Simultaneous in-field boost for patients with 1 to 4 brain metastasis/es treated with volumetric modulated arc therapy: a prospective study on quality-of-life

التفاصيل البيبلوغرافية
العنوان: Simultaneous in-field boost for patients with 1 to 4 brain metastasis/es treated with volumetric modulated arc therapy: a prospective study on quality-of-life
المؤلفون: Weber, Damien C, Caparrotti, Francesca, Laouiti, Mohamed, Malek, Karim
بيانات النشر: BioMed Central Ltd.
سنة النشر: 2011
المجموعة: BioMed Central
الوصف: Purpose To assess treatment toxicity and patients' survival/quality of life (QoL) after volumetric modulated arc therapy (VMAT) with simultaneous in-field boost (SIB) for cancer patients with 1 - 4 brain metastases (BM) treated with or without surgery. Methods and Materials Between March and December 2010, 29 BM patients (total volume BM, < 40 cm 3 ) aged < 80 years, KPS ≥ 70, RPA < III were included in this prospective trial. Whole brain VMAT (30 Gy) and a SIB to the BM (40 Gy) was delivered in 10 fraction. Mean age was 62.1 ± 8.5 years. Fifteen (51.7%) underwent surgery. KPS and MMSE were prospectively assessed. A self-assessed questionnaire was used to assess the QoL (EORTC QLQ-C30 with -BN20 module). Results As of April 2011 and after a mean FU of 5.4 ± 2.8 months, 14 (48.3%) patients died. The 6-month overall survival was 55.1%. Alopecia was only observed in 9 (31%) patients. In 3-month survivors, KPS was significantly ( p = 0.01) decreased. MMSE score remained however stable ( p = 0.33). Overall, QoL did decrease after VMAT. The mean QLQ-C30 global health status ( p = 0.72) and emotional functional ( p = 0.91) scores were decreased (low QoL). Physical ( p = 0.05) and role functioning score ( p = 0.01) were significantly worse and rapidly decreased during treatment. The majority of BN20 domains and single items worsened 3 months after VMAT except headaches ( p = 0.046) and bladder control ( p = 0.26) which improved. Conclusions The delivery of 40 Gy in 10 fractions to 1 - 4 BM using VMAT was achieved with no significant toxicity. QoL, performance status, but not MMSE, was however compromised 3 months after treatment in this selected cohort of BM patients.
نوع الوثيقة: report
اللغة: English
العلاقة: http://www.ro-journal.com/content/6/1/79Test
الإتاحة: http://www.ro-journal.com/content/6/1/79Test
حقوق: Copyright 2011 Weber et al; licensee BioMed Central Ltd.
رقم الانضمام: edsbas.7F2FC3EE
قاعدة البيانات: BASE